论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Colice G, Chisholm A, Dima AL, Reddel HK, Burden A, Martin RJ, Brusselle G, Popov TA, von Ziegenweidt J, Price DB
Received 13 September 2017
Accepted for publication 30 April 2018
Published 10 August 2018 Volume 2018:9 Pages 29—42
DOI https://doi.org/10.2147/POR.S151615
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Amy Norman
Peer reviewer comments 3
Editor who approved publication: Professor Jonathan Ling
Background: Observational research is essential to evaluate the real-life
effectiveness of asthma treatments and can now make use of outcomes derived
from electronic medical records.
Aim: The aim of this study was to investigate the
utility of several database outcome measures in asthma.
Methods: This study identified cohorts of patients with
active asthma from a UK primary care database – Optimum Patient Care Research
Database – approximately 10% of which was prospectively supplemented with
questionnaire data. The “Questionnaire cohort” included patients aged 18–60
years with valid questionnaire data and 1 year of continuous primary care data.
Separate “ICS initiation” and “ICS step-up” cohorts included patients aged 5–60
years initiated on inhaled corticosteroids (ICSs), who had 1 year of continuous
primary care data before, and after, this index visit. Database measures of
asthma symptom control and exacerbations were identified in the Optimum Patient
Care Research Database and cross-tabulated with corresponding patient-reported
(questionnaire) data. Responsiveness of the database outcomes was analyzed,
using McNemar’s and Wilcoxon’s signed rank tests, and Poisson regression was
used to estimate the association between database outcomes and future risk of
database exacerbations, in the ICS initiation cohort.
Results: The final study included 2,366 Questionnaire
cohort patients and 51,404 ICS initiation patients. Agreement between
patient-reported and database-recorded exacerbations was fair (kappa 0.35).
Following the initiation of ICS, database risk domain asthma control (based on
exacerbations) improved (proportion of patients with uncontrolled asthma
decreased from 24.9% to 18.6%; P <0.001) and
mean number of database exacerbations decreased from 0.09 to 0.08 per patient
per year (P =0.001). However, another measure
of asthma control which includes short-acting beta-agonist prescription as part
of the definition did not show this improvement. Patients with prior
exacerbations had a higher risk of future exacerbation (rate ratio [95%
confidence interval], 3.23 [3.03–3.57]).
Conclusion: Asthma control and exacerbations derived from
primary care databases were responsive, with the exception of short-acting
beta-agonist prescriptions, and useful for risk prediction.
Keywords: electronic
health records, real-life effectiveness, asthma control, asthma exacerbations,
validation study
摘要视频链接:Validated database severe
exacerbations and asthma control measures